Dara BioSciences granted T3D Therapeutics exclusive, worldwide rights to develop and commercialize DB959 to treat Alzheimer's disease (AD)

Dara BioSciences Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

$12.9m on 06/21/2013 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

T3D Therapeutics Inc.

U.S. / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced